Virtus Health Ltd (ASX:VRT) is an assisted reproductive services provider with operations in Australia, Denmark, Singapore and the United Kingdom. The company is headquartered in Sydney and is currently the largest in vitro fertilisation provider in Australia.
The S&P/ASX 200 (ASX: XJO) delivered a strong finish to the week as Appen (ASX:APX) and Tabcorp (ASX:TAH) shares were in the news.
The S&P/ASX 200 (ASX: XJO) finished the week on a high note, gaining 1.9% on the back of an incredible surge in the technology sector.
It was another volatile day for the S&P/ASX 200 (ASX: XJO) on Monday as Virtus (ASX:VRT) and ResApp (ASX:RAP) shares made headlines.
The S&P/ASX 200 (ASX: XJO) was dragged down 0.6% on Thursday as Magellan (ASX:MFG) and Ardent Leisure (ASX:ALG) shares made headlines.
The week ended on a negative note with the S&P/ASX 200 (ASX: XJO) closing down on Friday as markets oscillate between optimism and pessimism.
The Australian share market continued the post-invasion recovery, with the S&P/ASX 200 (INDEXASX:XJO) gaining 0.7% to begin the month of March.
The Virtus Health Ltd (ASX:VRT) share price is in focus as elective surgeries are suspended due to the current Omicron COVID-19 wave.
The S&P/ASX 200 (ASX: XJO) finished broadly flat on Tuesday as Woolworths (ASX:WOW) and Mesoblast (ASX:MSB) shares were in the news.
Virtus Health Ltd (ASX: VRT) released its half-year result for FY21 on Tuesday, with the share price rising 2.3% on the day.
